Company Overview and News

 
American Axle & Manufacturing Sees Hammer Chart Pattern: Time to Buy?

12h zacks
American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because AXL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
AXL

5
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman

12h zacks
Chicago, IL – October 15, 2018 - Stocks in this week’s article include: Manulife Financial Corporation (MFC - Free Report) , Jazz Pharmaceuticals plc (JAZZ - Free Report) , DaVita Inc. (DVA - Free Report) , American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) and Huntsman Corp. (HUN - Free Report) .
WFCNP JAZZ AXL HUN VSH WFC MFC 0945 HEAR MFC

 
5 Safe Stocks to Buy With Low Price-to-Book Ratios

2018-10-13 investorplace
In the present volatile stock market, value analysis, is becoming more and more important. When analyzing value stocks, most investors use the P/E ratio to search for lucrative stocks, but there are other ratios that an investor can consider, like the price-to-sales ratio (P/S) and price-to-book (P/B) ratio. The P/S ratio is simply price divided by sales. One of the reasons P/S is a better choice is because it looks at sales rather than earnings like the price-to-earnings ratio.
JAZZ AXL ON MFC HUN 0945 MFC DVA

7
5 Low Price-to-Book Stocks to Buy in a Volatile Market

2018-10-12 zacks
In the present volatile stock market, value analysis, is becoming more and more important. In value stock analysis, most investors use the P/E ratio to search for lucrative stocks but there are other ratios that an investor can consider like price-to-sales ratio (P/S) and price-to-book (P/B) ratio. The P/S ratio is simply price divided by sales. One of the reasons Price to Sales ratio is a better choice is because it looks at sales rather than earnings like the P/E ratio.
DUKH JAZZ AXL DUK ON MFC HUN 0945 MFC

17
Zacks.com featured highlights include: ArcBest, American Axle, MetLife and Prudential

2018-10-11 zacks
Chicago, IL – October 11, 2018 - Stocks in this week’s article are ArcBest Corp. (ARCB - Free Report) , American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) , MetLife, Inc. (MET - Free Report) and Prudential Financial, Inc. (PRU - Free Report) .
PRU STZ.B ARCB AXL PRH PFK MET STZ URBN PRU PJH

26
Zacks.com featured highlights include: American Axle, Toll Brothers, Raymond James, Gaming and Leisure and SS&C

2018-10-11 zacks
Chicago, IL – October 11, 2018 - Stocks in this week’s article are American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) , Toll Brothers, Inc. (TOL - Free Report) , Raymond James Financial, Inc. (RJF - Free Report) , Gaming and Leisure Properties, Inc. (GLPI - Free Report) and SS&C Technologies Holdings, Inc. (SSNC - Free Report) .
STZ.B TOL AXL SSNC RJD GLPI STZ URBN RJF

7
Sonic Automotive (SAH) Expands EchoPark Store in Charlotte

2018-10-09 zacks
Sonic Automotive, Inc. (SAH - Free Report) has announced that it is expanding its EchoPark Automotive to Charlotte, NC. Notably, introduced in 2014, EchoPark has already been well accepted by customers in Denver, Colorado, Dallas and San Antonio, Texas. The company is likely to witness similar customer adulation this time around too. Per CarFax, EchoPark model sells almost new vehicles at 20-40% less price than new vehicles.
NAV AXL SAH ALSN

4
Fiat Chrysler to Produce Plug-in Hybrid Version of Renegade

2018-10-09 zacks
Fiat Chrysler Automobiles N.V. (FCAU - Free Report) has announced that it started arrangements for the production of plug-in hybrid version of Jeep Renegade, per Reuters. This is in sync with the company’s plan to move ahead with its electrification drive to comply with stricter emission regulations. Notably, in order to become fully compliant with emissions regulations, this seventh largest automaker in the world spelled out a plan in June to invest €9 billion (£7.
NAV AXL ALSN FCAU

 
American Axle (AXL) Q2 Earnings Beat Estimates, Gain Y/Y

2018-08-06 zacks
Shares of American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) have gained 6.3% in a day’s trading, following the second-quarter 2018 earnings release. The company posted adjusted earnings of $1.23 per share for the reported quarter, beating the Zacks Consensus Estimate of $1.12. In second-quarter 2017, adjusted earnings were 99 cents.
FOXF AXL BGSF FUN

 
American Axle & Manufacturing Holdings, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-03 seekingalpha
The following slide deck was published by American Axle & Manufacturing Holdings, Inc. in conjunction with their 2018 Q2 earnings call.
AXL

14
Honda (HMC) to Report Q1 Earnings: What's in the Cards?

2018-07-26 zacks
Honda Motor Co., Ltd. (HMC - Free Report) is expected to report first-quarter fiscal 2019 (ended June 2018) results on Jul 31. Last reported quarter, the company delivered a positive surprise of 21.7%. In fact, Honda surpassed expectations in each of the trailing four quarters with an average beat of 41.2%.
CMQMY OSK AXL GM CMI

5
Johnson Controls (JCI) Q3 Earnings: What's in the Cards?

2018-07-25 zacks
Johnson Controls International plc (JCI - Free Report) is set to report third-quarter fiscal 2018 results before the opening bell on Jul 31.
FOXF LMT AXL BP BP.A BP.B VC BP BPAQF JCI NEE

3
Will Auto & Energy Sales Drive Tesla's (TSLA) Q2 Earnings?

2018-07-25 zacks
Tesla, Inc. (TSLA - Free Report) is scheduled to announce second-quarter 2018 results on Aug 1. In the last reported quarter, both top and bottom lines beat the Zacks Consensus Estimate. Also, the figures were higher compared with the prior-year quarter.
MGA AXL TM MG 7203 TYT TOYOF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to AXL / American Axle & Manufacturing Holdings, Inc. on message board site Silicon Investor.

biotech taxloss 2001 biotech taxloss 2001 biotech taxloss 2001 taxloss selling taxloss selling taxloss selling
TJT Inc. (AXLE) - Undervalued Special Situation TJT Inc. (AXLE) - Undervalued Special Situation TJT Inc. (AXLE) - Undervalued Special Situation Mark Schultz of Traders Faxline Mark Schultz of Traders Faxline Mark Schultz of Traders Faxline
CUSIP: 024061103